BioSpace News Archive

Increasing prevalence of cardiovascular diseases such as congenital heart diseases, cardiac arrhythmia, stroke and cardiac arrest across the globe, high penetration of internet, and rising investments in research and development activities are expected to drive global market revenue growth.

The report further provides details about each segments and regions covered in the global Preclinical Tomography System market. The data has been collected through extensive primary and secondary research and is validated by experts in the industry.

UCB (Euronext: UCB) today announced the publication in JAMA Neurology of its multi-center, double-blind, placebo-controlled, parallel-group, randomized Phase 3 trial demonstrating that FINTEPLA 0.7 mg/kg/day, when added to a patient’s current anti-epileptic treatment regimen for seizures associated with LGS, is effective in reducing the frequency of drop seizures.

The board of directors of Eli Lilly and Company has declared a dividend for the second quarter of 2022 of $0.98 per share on outstanding common stock.

Fresenius Kabi announced today it has introduced Bortezomib for Injection, a new generic equivalent to Velcade® in the U.S. and the newest addition to the most comprehensive injectable oncology portfolio in the industry.

There is a growing demand for treatments that offer tissue regeneration. Since pulsed electromagnetic field (PEMF) external devices product segment is projected for aggressive growth in the bone growth stimulators market, healthcare providers are becoming increasingly aware about its advantages.

There is a growing demand for handheld imaging devices in dentistry and orthopedics.

The global hospital infection therapeutics market was valued at US$ 14.4 Bn in 2017 and is projected to expand at a significant CAGR of 2.4% from 2018 to 2026.

The global hepatitis therapeutics market has been segmented based on disease type, drug class, distribution channel, and region.

The global spine surgery robots market was valued at more than US$ 75 Mn in 2017 and is anticipated to reach US$ 320 Mn by 2026.